Imatinib: a selective tyrosine kinase inhibitor
- 1 September 2002
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 38, S19-S27
- https://doi.org/10.1016/s0959-8049(02)80599-8
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- The Sequence of the Human GenomeScience, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Antagonists of protein–protein interactionsCell Chemical Biology, 2000
- Tyrosine kinase inhibitors in cancer treatment (Part II)Expert Opinion on Therapeutic Patents, 1998
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997
- Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitorsBioorganic & Medicinal Chemistry Letters, 1996
- Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitorsJournal of Medicinal Chemistry, 1993
- Pyrido[2,3-d]pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and their derivativesJournal of Medicinal Chemistry, 1975